ACT	Adriamycin: Cytoxan, and Taxotere
AR	Androgen receptor
CI	confidence interval
DFS	disease-free survival
DRFS	distant recurrence-free survival
EGFR	epidermal growth factor receptor
ER	estrogen receptor
HER2	human epidermal growth factor receptor 2
H&E	hematoxylin and eosin staining
HR	Hazard Ratio
IDFS	invasive disease-free survival
IHC	immunohistochemistry
LN	lymph node
MBC	metastatic breast cancer
mTNBC	metastatic TNBC
mTOR	the mammalian target of rapamycin
NACT	neoadjuvant chemotherapy
OS	overall survival
PARP	poly-ADP-ribose polymerase
pCR	pathological complete response
PD-1	programmed cell death receptor-1
PD-L1	programmed death ligand-1
PFS	progression-free survival
PI3K	phosphoinositide-3 kinase
pIR	pathological incomplete response
PKB	protein kinase B (AKT)
PR	progesterone receptor
RCB	Residual Cancer Burden
SEER	Surveillance, Epidemiology and End Results Program
SIAH	human homologues of Drosophila Seven-In-Absentia
SOC	standard of care
TIL	tumor infiltrating lymphocytes
TME	tumor microenvironment
TNBC	triple-negative breast cancer
TNM	tumor size, lymph node status, metastasis
Trop-2	Trophoblast cell-surface antigen